Oral Microparticulate Multivalent HIV-1 Peptide Vaccine for Immune Response Induction

This study focuses on finding a way to prevent HIV-1 infection. Researchers are testing a new oral vaccine called UBI Microparticulate Monovalent HIV-1 MN Peptide Immunogen. This vaccine is unique because it's designed to gradually break down over time, potentially stimulating both local and overall immune responses. The study is important because current vaccine formulations may not provide all the necessary characteristics for an effective HIV vaccine. This research aims to address these challenges and meet the unmet needs in HIV prevention. Participants in this study will be given the oral vaccine at months 0, 1, and 6. There are two dose regimens: either a low dose taken daily for 3 days, or a single higher dose. For each regimen, 12 volunteers will receive the vaccine, while 4 volunteers will receive a placebo. Participants will be monitored for a year, and then contacted once or twice yearly for the next 5 years to check on their health status. The study measures the safety and immune response triggered by the vaccine.